Repare Therapeutics to Present at Virtual Investor Conferences in January

Rhea-AI Summary

Repare Therapeutics, Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced CEO Lloyd M. Segal's participation in two virtual investor conferences. The H.C. Wainwright Virtual BioConnect Conference will be from January 11-14, 2021, with a pre-recorded presentation available on January 11 at 6:00 a.m. ET. The 39th Annual J.P. Morgan Healthcare Conference is scheduled for January 14, 2021, at 8:20 a.m. ET, featuring a live webcast. Repare focuses on developing targeted cancer therapies through its SNIPRx® platform, with notable products like RP-3500.

Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences:

H.C. Wainwright Virtual BioConnect Conference
Date: Monday, January 11 – Thursday, January 14

39^th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 14
Time: 8:20 a.m. Eastern Time

The H.C. Wainwright presentation will be pre-recorded and available on Monday, January 11, 2021, at 6:00 a.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A live webcast of the J.P. Morgan presentation will be available in the same section of the website. A replay of both webcasts will be archived for 30 days following each presentation date.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005027/en/

FAQ

When is Repare Therapeutics presenting at the H.C. Wainwright Virtual BioConnect Conference?

Repare Therapeutics will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021.

What time is Repare Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Repare Therapeutics' presentation at the J.P. Morgan Healthcare Conference is scheduled for January 14, 2021, at 8:20 a.m. Eastern Time.

How can I access Repare Therapeutics' presentations?

You can access Repare Therapeutics' presentations via the Investor section of their website, with the H.C. Wainwright presentation available on January 11 and a live webcast for the J.P. Morgan conference.

What is the ticker symbol for Repare Therapeutics?

The ticker symbol for Repare Therapeutics is RPTX.

What is SNIPRx® and how does it relate to Repare Therapeutics?

SNIPRx® is Repare Therapeutics' proprietary platform used for the discovery and development of targeted cancer therapies.

What is the lead product candidate of Repare Therapeutics?

Repare Therapeutics' lead product candidate is RP-3500, which is a potential ATR inhibitor.